Delisting of the shares of Dignitana: last day of trading 24 June 2025
10 juni, 17:28
10 juni, 17:28
Delisting of the shares of Dignitana: last day of trading 24 June 2025
In accordance with Nasdaq Stockholm AB’s decision following application from the board of directors of Dignitana AB, the shares of Dignitana will be delisted from Nasdaq First North Growth Market. The last day of trading is 24 June 2025.
About Dignitana
Dignitana AB is a Swedish medical technology company specializing in scalp cooling. The company produces The DigniCap® Scalp Cooling System, a patented medical cooling device that offers cancer patients the ability to minimize hair loss during chemotherapy. FDA cleared since 2015, DigniCap provides continuous cooling with high efficacy, safety and patient comfort. Hailed internationally as a life-changing medical advancement for cancer patients, The DigniCap Scalp Cooling System was invented in 1999 by a Swedish Oncology nurse and has been available in Europe since 2001. Dignitana AB is listed on Nasdaq First North Growth Market in Sweden with headquarters in Lund, Sweden and US operations based in Dallas, Texas in the United States. Company subsidiaries are Dignitana, Inc. in the United States and Dignitana S.r.l. in Italy. Certified Adviser is Redeye AB. Learn more at www.dignitana.com or www.dignicap.com.
For More Information Contact
Melissa Bourestom, Chief Communications Officer, melissa.bourestom@dignitana.com +1 469-518-5031
10 juni, 17:28
Delisting of the shares of Dignitana: last day of trading 24 June 2025
In accordance with Nasdaq Stockholm AB’s decision following application from the board of directors of Dignitana AB, the shares of Dignitana will be delisted from Nasdaq First North Growth Market. The last day of trading is 24 June 2025.
About Dignitana
Dignitana AB is a Swedish medical technology company specializing in scalp cooling. The company produces The DigniCap® Scalp Cooling System, a patented medical cooling device that offers cancer patients the ability to minimize hair loss during chemotherapy. FDA cleared since 2015, DigniCap provides continuous cooling with high efficacy, safety and patient comfort. Hailed internationally as a life-changing medical advancement for cancer patients, The DigniCap Scalp Cooling System was invented in 1999 by a Swedish Oncology nurse and has been available in Europe since 2001. Dignitana AB is listed on Nasdaq First North Growth Market in Sweden with headquarters in Lund, Sweden and US operations based in Dallas, Texas in the United States. Company subsidiaries are Dignitana, Inc. in the United States and Dignitana S.r.l. in Italy. Certified Adviser is Redeye AB. Learn more at www.dignitana.com or www.dignicap.com.
For More Information Contact
Melissa Bourestom, Chief Communications Officer, melissa.bourestom@dignitana.com +1 469-518-5031
Fortnox-budet
Investmentbolagen
Storbritannien
Aktieråd
Fortnox-budet
Investmentbolagen
Storbritannien
Aktieråd
1 DAG %
Senast
Saab
Igår, 16:31
Stort inflöde till försvars-ETF:er
OMX Stockholm 30
1 DAG %
Senast
2 481,49